Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides
AssigneeBristol-Myers Squibb Company
InventorsBrett T. Watson, Astrid A. Ortiz
Life of this patent
Estimating the term…
Abstract
New central nervous system agents conform to formula I: ##STR1## wherein R=H or C.sub.1-4 alkoxy; X=CH or N; Y=NH, O or S; Z=C.sub.1-4 alkyl, C.sub.3-6 cycloalkyl, C.sub.2-3 alkenyl, NH.sub.2, C.sub.1-4 alkylamino, or C.sub.1-4 alkoxyalkyl, with the proviso that Z may not be CH.sub.3 when R=H, X=CH, and Y=NH and Z may not be CH.sub.3 when R=H, X=N and Y=NH and NHC(O)Z is in the para- position.
Claims24
A method of eliciting an anticonvulsive effect in a mammal in need thereof comprising the step of administering to said mammal an anticonvulsive amount of a compound of formula I or a pharmaceutically acceptable salt thereof:
- ##STR17## wherein R=H or C.sub.1-4 alkoxy;
- X=CH or N;
- Y=NH, O or S;
- Z=C.sub.1-4 alkyl, C.sub.3-6 cycloalkyl, C.sub.2-3 alkenyl, NH.sub.2, C.sub.1-4 alkylamino, or C.sub.1-4 alkoxyalkyl, with the proviso that Z may not be CH.sub.3 when R.dbd.H, X.dbd.CH, and Y.dbd.NH and Z may not be CH.sub.3 when R.dbd.H, X.dbd.N and Y.dbd.NH and NHC(O)Z is in the para-position.
A method of eliciting an anticonvulsive effect in a mammal in need thereof comprising the step of administering to said mammal an anticonvulsive amount of a compound selected from the group consisting of:
- N-[2-(1H-benzimidazol-2-yl)phenyl]-N'-methyl urea;
- N-[2-(5-methoxy-1H-benzimidazol-2-yl)phenyl] acetamide;
- N-[2-(benzimidazol-2-yl)phenyl]propanamide;
- N-[2-(benzoxazol-2-yl)phenyl]-N'-methyl urea ;
- N-[2-(1H-benzimidazol-2-yl)phenyl] methoxyacetamide;
- N-[2-(5-methoxy-1H-benzimidazol-2-yl)phenyl] methoxy acetamide;
- N-[3-(1H-imidazo[4,5-b]pyridin-2-yl)phenyl] acetamide;
- N-[2-(1H-benzimidazol-2-yl)phenyl] cyclopropane carboxamide;
- N-[2-(1H-benzimidazol-2-yl)phenyl]-trans-2-butenamide;
- N-[2-(benzimidazol-2-yl)phenyl] propanamide;
- and N-[2-(benzthiazol-2-yl)phenyl]acetamide.
A method of eliciting a melatonergic effect in a mammal in need thereof comprising the step of administering to said mammal a melatonergic amount of a compound of formula I or a pharmaceutically acceptable salt thereof:
- ##STR18## wherein R=H or C.sub.1-4 alkoxy;
- X=CH Or N;
- Y=NH, O or S;
- Z=C.sub.1-4 alkyl, C.sub.3-6 cycloalkyl, C.sub.2-3 alkenyl, NH.sub.2, C.sub.1-4 alkylamino, or C.sub.1-4 alkoxyalkyl, with the proviso that Z may not be CH.sub.3 when R.dbd.H, X.dbd.CH, and Y.dbd.NH and Z may not be CH.sub.3 when R.dbd.H, X.dbd.N and Y.dbd.NH and NHC(O)Z is the para-position.
A method of eliciting a melatonergic effect in a mammal in need thereof comprising the step of administering to said mammal a melatonergic amount of a compound selected from the group consisting of:
- N-[2-(1H-benzimidazol-2-yl)phenyl]-N'-methyl urea;
- N-[2-(5-methoxy-1H-benzimidazol-2-yl)phenyl] acetamide;
- N-[2-(benzimidazol-2-yl)phenyl]-propanamide;
- N-[2-(benzoxazol-2-yl)phenyl]-N'-methyl urea;
- N-[2-(1H-benzimidazol-2-yl)phenyl] methoxyacetamide;
- N-[2-(5-methoxy-1H-benzimidazol-2-yl)phenyl] methoxy acetamide;
- N-[3-(1H-imidazo[4,5,b]pyridin-2-yl)phenyl] acetamide;
- N-[2(1H-benzimidazol-2-yl)phenyl]cyclopropane carboxamide;
- N-[2-(1H-benzimidazol-2-yl)phenyl]-trans-2-butenamide;
- N-[2-(benzimidazol-2-yl)phenyl] propanamide;
- and N-[2-(benzthiazol-2-yl)phenyl] acetamide.
Dependencies are inferred from the claim text.